The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
Friday's edition of Forbes Daily covers the investigation of the deadly plane crash, OpenAI's whopping valuation, sluggish ...
The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...
Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
While America retains a gold standard for airline safety, there are stresses on the US air travel system that have been apparent in a series of near tragedies in recent years. Aviation experts have ...